Inhibitor Therapeutics, Inc. (INTI)
OTCMKTS · Delayed Price · Currency is USD
0.0418
-0.0051 (-10.87%)
Jun 30, 2025, 3:20 PM EDT

Inhibitor Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
81016375613
Upgrade
Market Cap Growth
-28.45%-34.56%-57.47%-34.06%332.17%-36.77%
Upgrade
Enterprise Value
446426117
Upgrade
Last Close Price
0.050.060.090.100.150.03
Upgrade
PE Ratio
---3.12--
Upgrade
PB Ratio
5.985.223.004.49-15.59-3.89
Upgrade
P/TBV Ratio
5.985.223.004.49--
Upgrade
P/OCF Ratio
---3.17--
Upgrade
Debt / Equity Ratio
0.06--0.05-0.06-0.03
Upgrade
Quick Ratio
45.637.9013.2917.610.050.18
Upgrade
Current Ratio
46.688.0313.4517.640.090.25
Upgrade
Return on Equity (ROE)
-109.75%-91.88%-44.57%517.86%--
Upgrade
Return on Assets (ROA)
-36.15%-31.22%-20.34%-6.83%-213.47%-128.30%
Upgrade
Return on Capital (ROIC)
-73.19%-62.89%-30.42%-15.47%--
Upgrade
Earnings Yield
-40.67%-32.24%-19.12%32.53%-0.53%-8.10%
Upgrade
Buyback Yield / Dilution
-0.18%-0.18%53.04%2.67%-1.16%-0.40%
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.